Neuroleptic malignant syndrome without fever after addition of oxcarbazepine to long-term treatment with amisulpride.
Our goal was to report a case of malignant neuroleptic syndrome in a patient administered with both oxcarbazepine (OXCBZ) and amisulpride (AM). We present a case of a young man who presented with symptoms of malignant neuroleptic syndrome after progressive titration of OXCBZ (1,200 mg) added to the long-term treatment with AM (800 mg). After discontinuation of AM and administration of dopaminergic drugs, his clinical symptoms improved gradually. This case suggests that clinicians should consider the risk of neuroleptic malignant syndrome when OXCBZ is coadministered to patients undergoing long-term treatment with neuroleptics.